Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veliparib + floxuridine
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
Veliparib + floxuridine is an investigational combination therapy consisting of the PARP inhibitor veliparib and the antimetabolite floxuridine. Veliparib (ABT-888) is a small molecule inhibitor of PARP-1 and PARP-2, enzymes critical for the repair of single-strand DNA breaks via the base excision repair pathway. Inhibition of PARP leads to the accumulation of DNA damage and cell death, particularly in tumors with homologous recombination deficiencies. Floxuridine is a pyrimidine analog that is converted to 5-fluorodeoxyuridine monophosphate, a potent inhibitor of thymidylate synthase, which is essential for DNA synthesis. This combination is being studied for its potential synergistic effects in treating advanced epithelial ovarian, primary peritoneal, and fallopian tube cancers, where the inhibition of DNA repair by veliparib may sensitize tumor cells to the DNA-damaging effects of floxuridine.
- Other names
- veliparib and floxuridineABT-888 and floxuridineABT888 and floxuridineABT 888 and floxuridineABT-888 + FUDR
02
Targets
SLC47A1 (Multidrug and toxin extrusion transporter 1)MATE2-K (Multidrug and toxin extrusion protein 2)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)OCT2 (Organic cation transporter 2)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TS (Thymidylate synthase)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on veliparib + floxuridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veliparib + floxuridine.